Skip to content

News

News

Press Releases

2014 | 2013 | 2012 | Archive
Keyword Search
 
DateTitle 
12/08/14ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders
Data Demonstrate a Decreased Burden Among Caregivers of Patients with Parkinson’s Disease Psychosis Treated with NUPLAZID™ (Pimavanserin) SAN DIEGO--(BUSINESS WIRE)--Dec. 8, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the presentation of caregiver burden data from its Phase III program with NUPLAZID™ (pimavanserin) for Parkinson’s disease psychosis (PDP) at the 10th Annual International Congress of Non-Motor Dysfunctions ... 
Printer Friendly Version
11/25/14ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Nov. 25, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: The Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014, at 10:30 a.m. Eastern Time in New Yo... 
Printer Friendly Version
11/13/14ACADIA Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference on November 20, 2014
SAN DIEGO--(BUSINESS WIRE)--Nov. 13, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies 2014 Global Healthcare Conference on Thursday, November 20, 2014, at 9:20 a.m. GMT in London. A live webc... 
Printer Friendly Version
11/10/14ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results and Updates Timing of NUPLAZID™ NDA Submission
SAN DIEGO--(BUSINESS WIRE)--Nov. 10, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the third quarter ended September 30, 2014 and provided an update on the timing of its NUPLAZID™ (pimavanserin) New Drug ... 
Printer Friendly Version
11/03/14ACADIA Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 10, 2014
ACADIA to Host Conference Call and Webcast on Monday, November 10, 2014, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Nov. 3, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financi... 
Printer Friendly Version
09/02/14ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis
FDA Decision Highlights Significant Unmet Need in the Treatment of Parkinson’s Disease Psychosis SAN DIEGO--(BUSINESS WIRE)--Sep. 2, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has ... 
Printer Friendly Version
08/28/14ACADIA Pharmaceuticals Announces Trade Name NUPLAZID™ for Pimavanserin
SAN DIEGO--(BUSINESS WIRE)--Aug. 28, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has provisionally accepted the trade name “NUPLAZID”™ for pimavanserin. NUPLAZID is a selective serotonin inver... 
Printer Friendly Version
08/05/14ACADIA Pharmaceuticals Reports Second Quarter 2014 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the second quarter ended June 30, 2014. ACADIA reported a net loss of $21.5 million, or $0.22 per common share, ... 
Printer Friendly Version
07/29/14ACADIA Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 5, 2014
ACADIA to Host Conference Call and Webcast on Tuesday, August 5, 2014, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Jul. 29, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financia... 
Printer Friendly Version
07/15/14ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer
SAN DIEGO--(BUSINESS WIRE)--Jul. 15, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, announced the appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective today. Mr. Davis will report to Uli Hack... 
Printer Friendly Version
06/17/14ACADIA Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference on June 24, 2014
SAN DIEGO--(BUSINESS WIRE)--Jun. 17, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24, 2014, at 1:30 p.m. Eastern Time in New York City. ... 
Printer Friendly Version
05/27/14ACADIA Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014
SAN DIEGO--(BUSINESS WIRE)--May 27, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014, at 10:00 a.m. Eastern Time in New York City. A ... 
Printer Friendly Version
05/06/14ACADIA Pharmaceuticals Reports First Quarter 2014 Financial Results
SAN DIEGO--(BUSINESS WIRE)--May 6, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2014. ACADIA reported a net loss of $17.8 million, or $0.19 per common share, ... 
Printer Friendly Version
05/01/14ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--May 1, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: The Deutsche Bank 39th Annual Health Care Conference on Thursday, May 8, ... 
Printer Friendly Version
04/29/14ACADIA Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 6, 2014
ACADIA to Host Conference Call and Webcast on Tuesday, May 6, 2014, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Apr. 29, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial r... 
Printer Friendly Version
04/01/14ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014
SAN DIEGO--(BUSINESS WIRE)--Apr. 1, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014, at 8:40 a.m. Eastern Time in New York City. A l... 
Printer Friendly Version
03/05/14ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Mar. 5, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: The Cowen and Company 34th Annual Health Care Conference on Wednesday, M... 
Printer Friendly Version
03/04/14ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--Mar. 4, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing of an underwritten public offering of 6,400,000 shares of its common stock, offered at a price to the public of $28.50 per share. The gross proceeds from this offering to ACADIA are expected to be $182.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted... 
Printer Friendly Version
03/03/14ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--Mar. 3, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC and J.P. Morgan Securities LLC are acting as the j... 
Printer Friendly Version
02/27/14ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2013
SAN DIEGO--(BUSINESS WIRE)--Feb. 27, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2013. ACADIA reported a net loss of $12.0 million, or $0.13 per common share,... 
Printer Friendly Version
02/20/14ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
ACADIA to Host Conference Call and Webcast on Thursday, February 27, 2014, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Feb. 20, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its financial resu... 
Printer Friendly Version
11/26/13ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Nov. 26, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: The Piper Jaffray 25th Annual Healthcare Conference on Tuesday, December 3, 2013, at 10:00 a.m. Eastern Time in New York City. The Oppenheimer 24th Annual Healthcare Conferen... 
Printer Friendly Version
11/14/13ACADIA Pharmaceuticals Announces Initiation of Phase II Trial with Pimavanserin for Alzheimer’s Disease Psychosis
SAN DIEGO--(BUSINESS WIRE)--Nov. 14, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for patients with Alzheimer’s disease psychosis (ADP). No drug is approve... 
Printer Friendly Version
11/06/13ACADIA Pharmaceuticals Reports Third Quarter 2013 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Nov. 6, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the third quarter ended September 30, 2013. ACADIA reported a net loss of $10.7 million, or $0.12 per common share, for the third quarter of 2013 com... 
Printer Friendly Version
10/31/13ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Parkinson’s Disease Psychosis Trial with Pimavanserin
SAN DIEGO--(BUSINESS WIRE)--Oct. 31, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the publication of data from its pivotal Phase III -020 Study with pimavanserin in patients with Parkinson’s disease psychosis (PDP) in the November 1, 2013 online issue of The Lancet. In the -020 ... 
Printer Friendly Version
10/30/13ACADIA Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 6, 2013
ACADIA to Host Conference Call and Webcast on Wednesday, November 6, 2013, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Oct. 30, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended Septem... 
Printer Friendly Version
09/03/13ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Sep. 3, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: The Morgan Stanley Global Healthcare Conference on Monday, September 9, 2013, at 9:25 a.m. Eastern Time in New York Cit... 
Printer Friendly Version
08/19/13ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer
SAN DIEGO--(BUSINESS WIRE)--Aug. 19, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced the appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer, effective today. Mr. Moore reports to ACADIA’s Chief Executive Officer, Uli Hacksell, Ph.D., and will be respons... 
Printer Friendly Version
08/06/13ACADIA Pharmaceuticals Reports Second Quarter 2013 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Aug. 6, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the second quarter ended June 30, 2013. ACADIA reported a net loss of $9.1 million, or $0.11 per common share, for the second quarter of 2013 compar... 
Printer Friendly Version
07/30/13ACADIA Pharmaceuticals to Announce Second Quarter 2013 Financial Results on August 6, 2013
ACADIA to Host Conference Call and Webcast on Tuesday, August 6, 2013, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Jul. 30, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, ... 
Printer Friendly Version
07/02/13ACADIA Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference on July 9, 2013
SAN DIEGO--(BUSINESS WIRE)--Jul. 2, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 8th Annual JMP Securities Healthcare Conference on Tuesday, July 9, 2013, at 1:00 p.m. Eastern Time at The St. Regis New York in New York City. A live webca... 
Printer Friendly Version
07/01/13ACADIA Pharmaceuticals Added to Russell 2000 Index
SAN DIEGO--(BUSINESS WIRE)--Jul. 1, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has been added to the Russell 2000 Index effective after the close of market on Friday, June 28, 2013, as part of Russell Investments’ annual index reconstitution. ACADIA also was added to th... 
Printer Friendly Version
06/18/13ACADIA Pharmaceuticals Announces Multiple Presentations of Data from Phase III Pimavanserin Program at the 17th International Congress of Parkinson’s Disease and Movement Disorders
SAN DIEGO--(BUSINESS WIRE)--Jun. 18, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, presented data today from its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), including data from its pivotal -020 Study and the related, open-label safety extension study, at a poster ... 
Printer Friendly Version
06/03/13ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical Development
SAN DIEGO--(BUSINESS WIRE)--Jun. 3, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that Allergan, Inc. (NYSE: AGN) has advanced an additional product candidate as a potential new treatment for glaucoma. The novel small molecule resulted from joint research conducted by the companie... 
Printer Friendly Version
05/29/13ACADIA Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 5, 2013
SAN DIEGO--(BUSINESS WIRE)--May 29, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2013, at 10:30 a.m. Eastern Time at the Grand Hyatt New York in New York City. A live webcast of ACADIA’s presentation will be accessible on the compa... 
Printer Friendly Version
05/20/13ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index
SAN DIEGO--(BUSINESS WIRE)--May 20, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: ^NBI) effective prior to today’s market open. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are cla... 
Printer Friendly Version
05/20/13ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--May 20, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the completion of an underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the full exercise of an option to purchase additional shares previously granted to the underwriters. All of the shares were offered by ACADIA at a price to the public of $12.50 per share. The gross proceeds from this offering to ACADIA were $115 million, before d... 
Printer Friendly Version
05/15/13ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--May 15, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock, offered at a price to the public of $12.50 per share. The gross proceeds from this offering to ACADIA are expected to be $100 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted the underwriters a 30-day option to purchas... 
Printer Friendly Version
05/14/13ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--May 14, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC and Cowen and Company, LLC are acting as the joint book-running managers for the offering. JMP Securities LLC and ... 
Printer Friendly Version
05/07/13ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results
SAN DIEGO--(BUSINESS WIRE)--May 7, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2013. ACADIA reported a net loss of $6.1 million, or $0.08 per common share, for the first quarter of 2013 compared to a net loss of $6.2 million, or $0.12 per common shar... 
Printer Friendly Version
04/30/13ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013
ACADIA to Host Conference Call and Webcast on Tuesday, May 7, 2013, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Apr. 30, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 201... 
Printer Friendly Version
04/25/13ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013
SAN DIEGO--(BUSINESS WIRE)--Apr. 25, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, 2013, at 8:00 a.m. Eastern Time at The Westin New York Grand Central Hotel in New York City. ... 
Printer Friendly Version
04/11/13ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA
Single Pivotal Phase III -020 Study and Other Supportive Data Sufficient for Future NDA Filing for the Treatment of Parkinson’s Disease Psychosis Conference Call and Webcast to Be Held Today, April 11, 2013, at 8:00 am Eastern Time SAN DIEGO--(BUSINESS WIRE)--Apr. 11, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurolo... 
Printer Friendly Version
03/20/13ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Mar. 20, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that Jeffrey Cummings, M.D., Sc.D., Director of Cleveland Clinic Lou Ruvo Center for Brain Health, presented detailed results today from ACADIA’s pivotal Phase III -020 Study with pimavanserin in pati... 
Printer Friendly Version
03/13/13ACADIA Pharmaceuticals to Present at the 25th Annual ROTH Conference on March 19, 2013
SAN DIEGO--(BUSINESS WIRE)--Mar. 13, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 25th Annual ROTH Conference on Tuesday, March 19, 2013, at 10:00 a.m. Pacific Time at The Ritz-Carlton in Laguna Niguel. A live webcast of ACADIA's presentation will be accessible on the company's website, www.... 
Printer Friendly Version
03/12/13ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
SAN DIEGO--(BUSINESS WIRE)--Mar. 12, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2012. ACADIA reported a net loss of $6.8 million, or $0.11 per common share, for the fourth quarter of 201... 
Printer Friendly Version
03/05/13ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013
ACADIA to Host Conference Call and Webcast on Tuesday, March 12, 2013, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Mar. 5, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year e... 
Printer Friendly Version
02/25/13ACADIA Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013
SAN DIEGO--(BUSINESS WIRE)--Feb. 25, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Cowen and Company 33rd Annual Health Care Conference on Monday, March 4, 2013, at 1:30 p.m. Eastern Time at the Boston Marriott Copley Place. A live we... 
Printer Friendly Version
02/05/13ACADIA Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference on February 12, 2013
SAN DIEGO--(BUSINESS WIRE)--Feb. 5, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it will present at the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013, at 10:00 a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. A live ... 
Printer Friendly Version
01/22/13ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Jan. 22, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the election of Stephen R. Biggar, M.D., Ph.D., to its board of directors. Dr. Biggar will fill a vacancy on ACADIA’s board and serve as a Class II director. The terms of the Class II directors ... 
Printer Friendly Version
12/20/12ACADIA Pharmaceuticals to Receive Funding from Fast Forward and EMD Serono for Multiple Sclerosis Program
Award Will Advance ACADIA’s Selective ER-Beta Agonist as a Potential New Neuroprotective MS Therapy through Collaborative Research with UCLA SAN DIEGO--(BUSINESS WIRE)--Dec. 20, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will receive funding from Fast... 
Printer Friendly Version
12/12/12ACADIA Pharmaceuticals Announces $86 Million Equity Financing
--Proceeds to Support Completion of Pimavanserin Phase III Program-- SAN DIEGO--(BUSINESS WIRE)--Dec. 12, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced a private placement equity financing pursuant to which ACADIA will receive gross proceeds of $86.4 million from... 
Printer Friendly Version
12/12/12ACADIA Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference Today, December 12, 2012
SAN DIEGO--(BUSINESS WIRE)--Dec. 12, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it will present at the Oppenheimer 23rd Annual Healthcare Conference later today, Wednesday, December 12, 2012, at 3:55 p.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. ... 
Printer Friendly Version
11/27/12ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson’s Disease Psychosis Trial
Pimavanserin Demonstrates Highly Significant Antipsychotic Efficacy and Maintenance of Motor Control in Parkinson’s Patients Significant Improvements Also Observed in All Secondary and Exploratory Measures Conference Call and Webcast to Be Held Today, November 27, 2012, at 8:00 am Eastern Time SAN DIEGO--(BUSINESS WIRE)--Nov. 27, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced successful top-lin... 
Printer Friendly Version
11/26/12ACADIA Pharmaceuticals to Host Conference Call and Webcast on November 27, 2012 at 8:00 AM EST to Present Top-Line Results from Its Pivotal Phase III Pimavanserin Parkinson’s Disease Psychosis Trial
SAN DIEGO--(BUSINESS WIRE)--Nov. 26, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will host a conference call and webcast at 8:00 a.m. Eastern Time on Tuesday, November 27, 2012 to present the top-line results from its pivotal Phase III trial with pimavanserin in patie... 
Printer Friendly Version
11/05/12ACADIA Pharmaceuticals Reports Third Quarter 2012 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the third quarter ended September 30, 2012. ACADIA reported a net loss of $2.4 million, or $0.04 per common share, for the third quarter of 2012... 
Printer Friendly Version
10/29/12ACADIA Pharmaceuticals to Announce Third Quarter 2012 Financial Results on November 5, 2012
ACADIA to Host Conference Call and Webcast on Monday, November 5, 2012, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended S... 
Printer Friendly Version
09/05/12ACADIA Pharmaceuticals Announces Completion of Enrollment in Phase III Pimavanserin Trial in Parkinson’s Disease Psychosis
Top-Line Data Expected in November 2012 SAN DIEGO--(BUSINESS WIRE)--Sep. 5, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis (PDP). ... 
Printer Friendly Version
08/29/12ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Aug. 29, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: The Stifel Nicolaus Healthcare Conference on Wednesday, September 5, 2012, at 3:50 p.m. Eastern Time at the Four S... 
Printer Friendly Version
08/08/12ACADIA Pharmaceuticals Reports Second Quarter 2012 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Aug. 8, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the second quarter ended June 30, 2012. ACADIA reported a net loss of $5.4 million, or $0.10 per common share, for the second quarter of 2012 co... 
Printer Friendly Version
08/01/12ACADIA Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 8, 2012
ACADIA to Host Conference Call and Webcast on Wednesday, August 8, 2012, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Aug. 1, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter... 
Printer Friendly Version
07/09/12ACADIA Pharmaceuticals Reports Promising Effects of Pimavanserin in Preclinical Model of Alzheimer’s Disease Psychosis
SAN DIEGO--(BUSINESS WIRE)--Jul. 9, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA’s proprietary product candidate currently in Phase III development for Parkinson’s disease psychosis, also may have ... 
Printer Friendly Version
07/09/12ACADIA Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference on July 13, 2012
SAN DIEGO--(BUSINESS WIRE)--Jul. 9, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 7th Annual JMP Securities Healthcare Conference on Friday, July 13, 2012, at 11:00 a.m. Eastern Time at The Peninsula Hotel in New York City. A live web... 
Printer Friendly Version
05/15/12ACADIA Pharmaceuticals to Webcast Educational Program on Parkinson’s Disease Psychosis on May 22, 2012
SAN DIEGO--(BUSINESS WIRE)--May 15, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will host a live webcast of its Educational Program on Parkinson’s Disease Psychosis to be held with analysts and investors in New York City on Tuesday, May 22, 2012, from 12:00 p.m. to 1:15 p.m. Eastern Time. The program will be h... 
Printer Friendly Version
05/08/12ACADIA Pharmaceuticals Reports First Quarter 2012 Financial Results
SAN DIEGO--(BUSINESS WIRE)--May 8, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2012. ACADIA reported a net loss of $6.2 million, or $0.12 per common share, for the first quarter of 2012 compared to a net loss of $5.8 million, or $0.12 per common sha... 
Printer Friendly Version
05/01/12ACADIA Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 8, 2012
ACADIA to Host Conference Call and Webcast on Tuesday, May 8, 2012, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--May 1, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2012 on Tuesday, May 8, 2012, after the U.S. financial... 
Printer Friendly Version
04/13/12ACADIA Pharmaceuticals to Present at the 19th Annual Future Leaders in the Biotech Industry Conference on April 20, 2012
SAN DIEGO, Apr 13, 2012 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 19th Annual Future Leaders in the Biotech Industry Conference on Friday, April 20, 2012, at 11:00 a.m. Eastern Time at the Millennium Broadway Hotel in New York City.... 
Printer Friendly Version
03/28/12ACADIA Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference on April 3, 2012
SAN DIEGO--(BUSINESS WIRE)--Mar. 28, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 11th Annual Needham Healthcare Conference on Tuesday, April 3, 2012, at 9:20 a.m. Eastern Time at The New York Palace Hotel in New York City. A live we... 
Printer Friendly Version
03/27/12ACADIA Pharmaceuticals Awarded New Grant from The Michael J. Fox Foundation for Development of Nurr1-RXR Selective Agonists to Treat Parkinson’s Disease
SAN DIEGO--(BUSINESS WIRE)--Mar. 27, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has been awarded a new grant from The Michael J. Fox Foundation (MJFF) for the further development of Nurr1-RXR selective agonists for the treatment of Parkinson’s disease. The grant of ... 
Printer Friendly Version
03/06/12ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011
SAN DIEGO--(BUSINESS WIRE)--Mar. 6, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2011. ACADIA reported a net loss of $5.3 million, or $0.10 per common share, for the fourth quarter of 2011... 
Printer Friendly Version
03/05/12ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.
SAN DIEGO--(BUSINESS WIRE)--Mar. 5, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc. (NYSE: AGN). The collaboration is currently focused on the discovery of new therapeutics for glaucoma and... 
Printer Friendly Version
02/29/12ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Feb. 29, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences: The Cowen and Company 32nd Annual Health Care Conference on Wednesday, March 7, 2012, at 10:00 a.... 
Printer Friendly Version
02/28/12ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2011 Financial Results on March 6, 2012
ACADIA to Host Conference Call and Webcast on Tuesday, March 6, 2012, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Feb. 28, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year... 
Printer Friendly Version
02/06/12ACADIA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012
SAN DIEGO--(BUSINESS WIRE)--Feb. 6, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012, at 9:30 a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. ... 
Printer Friendly Version
01/30/12ACADIA Pharmaceuticals Announces Election of Bill Wells to Its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Jan. 30, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the election of William (Bill) M. Wells to its board of directors. “We are very pleased to have Bill join ACADIA’s board,” said Uli Hacksell, Ph.D., ACADIA’s Chief Execut... 
Printer Friendly Version
12/07/11ACADIA Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 14, 2011
SAN DIEGO--(BUSINESS WIRE)--Dec. 7, 2011-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December 14, 2011, at 11:05 a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. ... 
Printer Friendly Version
11/09/11ACADIA Pharmaceuticals Reports Third Quarter 2011 Financial Results
SAN DIEGO, Nov 09, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter ended September 30, 2011. ACADIA reported a net loss of $5.1 million, or $0.10 per common share, for the third quarter of 2011 compared to a net loss of $4.2 million, or $0.11 ... 
Printer Friendly Version
11/07/11ACADIA Pharmaceuticals Advances AM-831 to Phase I Clinical Development in Collaboration with Meiji Seika Pharma
--FDA Accepts Investigational New Drug Application for AM-831-- SAN DIEGO, Nov 07, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, ... 
Printer Friendly Version
11/02/11ACADIA Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 9, 2011
ACADIA to Host Conference Call and Webcast on Wednesday, November 9, 2011, at 5:00 p.m. Eastern Time SAN DIEGO, Nov 02, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2011 on Wednesday, November 9, ... 
Printer Friendly Version
09/21/11ACADIA Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference on September 28, 2011
SAN DIEGO, Sep 21, 2011 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Sixth Annual JMP Securities Healthcare Conference on Wednesday, September 28, 2011, at 12:00 p.m. Eastern Time at The St. Regis Hotel in New York City. A live w... 
Printer Friendly Version
09/06/11ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12, 2011
SAN DIEGO, Sep 06, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011, at 4:30 p.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. A live webcast of ACADIA's presentation ... 
Printer Friendly Version
08/10/11ACADIA Pharmaceuticals Reports Second Quarter 2011 Financial Results
SAN DIEGO, Aug 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the second quarter ended June 30, 2011. ACADIA reported a net loss of $6.6 million, or $0.12 per common share, for the second quarter of 2011 compared to a net loss of $4.3 million, or $0.11 per... 
Printer Friendly Version
08/03/11ACADIA Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 10, 2011
ACADIA to Host Conference Call and Webcast on Wednesday, August 10, 2011, at 5:00 p.m. Eastern Time SAN DIEGO, Aug 03, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2011 on Wednesday, August 10, 2011, af... 
Printer Friendly Version
05/17/11ACADIA Pharmaceuticals Awarded Grant from National Institutes of Health for the Development of Novel ER-beta Agonists
SAN DIEGO, May 17, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has been awarded a grant from the National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health (NIH), for the development of novel estrogen receptor beta (ER-beta) agonist... 
Printer Friendly Version
05/10/11ACADIA Pharmaceuticals Reports First Quarter 2011 Financial Results
SAN DIEGO, May 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2011. ACADIA reported a net loss of $5.8 million, or $0.12 per common share, for the first quarter of 2011 compared to a net loss of $5.5 million, or $0.14 per... 
Printer Friendly Version
05/04/11ACADIA Pharmaceuticals to Present at the Tenth Annual JMP Securities Research Conference on May 11, 2011
SAN DIEGO, May 04, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Tenth Annual JMP Securities Research Conference on Wednesday, May 11, 2011, at 1:30 p.m. Pacific Time at The Ritz-Carlton Hotel in San Francisco. A live webcast of ACADIA's presentation will be accessi... 
Printer Friendly Version
05/03/11ACADIA Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 10, 2011
ACADIA to Host Conference Call and Webcast on Tuesday, May 10, 2011, at 5:00 p.m. Eastern Time SAN DIEGO, May 03, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2011 on Tuesday, May 10, 2011, after the ... 
Printer Friendly Version
04/01/11ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.
SAN DIEGO, Apr 01, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc. (NYSE: AGN). The collaboration is focused on the discovery of innovative new therapeutics for glaucoma and other ophthalmic indications and w... 
Printer Friendly Version
03/29/11ACADIA Pharmaceuticals to Present at the Tenth Annual Needham Healthcare Conference on April 5, 2011
SAN DIEGO, Mar 29, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Tenth Annual Needham Healthcare Conference on Tuesday, April 5, 2011, at 8:40 a.m. Eastern Time at The New York Palace Hotel in New York City. A live webcast of ACADIA's presentation will be accessible... 
Printer Friendly Version
03/10/11ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010
SAN DIEGO, Mar 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2010. ACADIA reported net income of $29.1 million, or $0.74 per common share, for the fourth quarter of 2010 compared to a net loss of $(8.7) million, or $(... 
Printer Friendly Version
03/03/11ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Financial Results on March 10, 2011
ACADIA to Host Conference Call and Webcast on Thursday, March 10, 2011, at 5:00 p.m. Eastern Time SAN DIEGO, Mar 03, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2010 on Thursday, March 10, 2011, aft... 
Printer Friendly Version
02/08/11ACADIA Pharmaceuticals to Present at the Thirteenth Annual BIO CEO & Investor Conference on February 15, 2011
SAN DIEGO, Feb 08, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Thirteenth Annual BIO CEO & Investor Conference on Tuesday, February 15, 2011, at 8:30 a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. A live webcast of ACADIA's presentation will be a... 
Printer Friendly Version
01/10/11ACADIA Pharmaceuticals Announces $15 Million Private Placement
--Proceeds to Support Advancement of Pimavanserin Phase III Program-- SAN DIEGO, Jan 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has entered into a securities purchase agreement for a private placement financing with a select group of institutional investors, including New Enterp... 
Printer Friendly Version
11/09/10ACADIA Pharmaceuticals Awarded Grant from The Michael J. Fox Foundation for the Development of Novel Nurr1-RXR Agonists to Treat Parkinson's Disease
SAN DIEGO, Nov 09, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has been awarded a grant from The Michael J. Fox Foundation (www.michaeljfox.org) for the development of novel Nurr1-RXR agonists for the treatment of Parkinson's disease. The grant of $300,000 was awarded under the Foundati... 
Printer Friendly Version
11/09/10ACADIA Pharmaceuticals Reports Third Quarter 2010 Financial Results
SAN DIEGO, Nov 09, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter ended September 30, 2010. ACADIA reported a net loss of $4.2 million, or $0.11 per common share, for the third quarter of 2010 compared to a net loss of $8.7 million, or $0.23 ... 
Printer Friendly Version
11/02/10ACADIA Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 9, 2010
ACADIA to Host Conference Call and Webcast on Tuesday, November 9, 2010, at 5:00 p.m. Eastern Time SAN DIEGO, Nov 02, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2010 on Tuesday, November 9, 2010... 
Printer Friendly Version
10/28/10ACADIA Pharmaceuticals Enters Agreement with Biovail to Conclude Collaboration and Regain North American Rights to Pimavanserin
ACADIA Now Holds Worldwide Rights; Receives $8.75 Million Payment to Continue Ongoing Phase III Trials in Parkinson's Disease Psychosis ACADIA Conference Call Scheduled for Today, October 28, at 9:00 A.M. Eastern Time SAN DIEGO, Oct 28, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has entered into an agreement with Biovail Laboratories International SRL ("BLS"), a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE and TS... 
Printer Friendly Version
09/22/10ACADIA Pharmaceuticals to Present at the Fifth Annual JMP Securities Healthcare Conference on September 28, 2010
SAN DIEGO, Sep 22, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Fifth Annual JMP Securities Healthcare Conference on Tuesday, September 28, 2010, at 8:30 a.m. Eastern Time at The New York Palace Hotel in New York City. A live webcast of ACADIA's presentation will b... 
Printer Friendly Version
09/07/10ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, Sep 07, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences: The Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 14, 2010, at 12:30 p.m. Eastern Time at The New York Palace Hotel in New York City. ... 
Printer Friendly Version
08/09/10ACADIA Pharmaceuticals Reports Second Quarter 2010 Financial Results
SAN DIEGO, Aug 09, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the second quarter ended June 30, 2010. ACADIA reported a net loss of $4.3 million, or $0.11 per common share, for the second quarter of 2010 compared to... 
Printer Friendly Version
08/02/10ACADIA Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 9, 2010
ACADIA to Host Conference Call and Webcast on Monday, August 9, 2010, at 5:00 p.m. Eastern Time SAN DIEGO, Aug 02, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2010... 
Printer Friendly Version
07/29/10ACADIA Pharmaceuticals Announces Initiation of New Phase III Trial with Pimavanserin for Parkinson's Disease Psychosis
SAN DIEGO, Jul 29, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated a new Phase III trial designed to evaluate the efficacy, tolerability and safety of pimavanserin as a treatment for patients with Parkinson's disease psychosis (PDP). ... 
Printer Friendly Version
06/02/10ACADIA Pharmaceuticals To Present at the Ninth Annual Needham Healthcare Conference on June 9, 2010
SAN DIEGO, Jun 02, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Ninth Annual Needham Healthcare Conference on Wednesday, June 9, 2010 at 3:20 p.m. Eastern Time at The New York Palace Hotel in New York City. A live webcast of A... 
Printer Friendly Version
05/10/10ACADIA Pharmaceuticals Reports First Quarter 2010 Financial Results
SAN DIEGO, May 10, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the first quarter ended March 31, 2010. ACADIA reported a net loss of $5.5 million, or $0.14 per common share, for the first quarter of 2010 compared to a... 
Printer Friendly Version
05/05/10ACADIA Pharmaceuticals to Present at the Ninth Annual JMP Securities Research Conference on May 12, 2010
SAN DIEGO, May 05, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Ninth Annual JMP Securities Research Conference on Wednesday, May 12, 2010 at 11:00 a.m. Pacific Time at The Ritz-Carlton Hotel in San Francisco. A live webcast o... 
Printer Friendly Version
05/03/10ACADIA Pharmaceuticals to Announce First Quarter 2010 Financial Results on May 10, 2010
ACADIA to Host Conference Call and Webcast on Monday, May 10, 2010, at 5:00 p.m. Eastern Time SAN DIEGO, May 03, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2010 ... 
Printer Friendly Version
04/14/10Dr. Joseph Friedman to Present Data From ACADIA Pharmaceuticals' First Phase III Trial With Pimavanserin for Parkinson's Disease Psychosis at the 62nd American Academy of Neurology Annual Meeting
SAN DIEGO, Apr 14, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Joseph H. Friedman, MD, will present data from ACADIA's previously reported Phase III trial (the -012 Study) with pimavanserin for Parkinson's disease psychosis (PDP) at the 62nd American Academy of Neurology Annual Meeting on ... 
Printer Friendly Version
03/09/10ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2009
SAN DIEGO, Mar 09, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its financial results for the fourth quarter and year ended December 31, 2009. ACADIA reported a net loss of $8.7 million, or $0.23 per common share, for the fourth quarter of 2009 compared t... 
Printer Friendly Version
03/02/10ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 9, 2010
ACADIA to Host Conference Call and Webcast on Tuesday, March 9, 2010, at 5:00 p.m. Eastern TimeSAN DIEGO, Mar 02, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the fourth quarter and year ended December 31, 2... 
Printer Friendly Version
02/01/10ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 8, 2010
SAN DIEGO, Feb 01, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the BIO CEO & Investor Conference 2010 on Monday, February 8, 2010, at 3:00 p.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. A live webcast of ACA... 
Printer Friendly Version
11/09/09ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Nov. 9, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter ended September 30, 2009. ACADIA reported a net loss of $8.7 million, or $0.23 per common share, for the third quarte... 
Printer Friendly Version
11/02/09ACADIA Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 9, 2009
ACADIA to Host Conference Call and Webcast on Monday, November 9, 2009, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Nov. 2, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the third quar... 
Printer Friendly Version
10/20/09ACADIA Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26, 2009
SAN DIEGO--(BUSINESS WIRE)--Oct. 20, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the BIOCOM Investor Conference 2009 on Monday, October 26, 2009 at 2:30 p.m. Pacific Time at the Hyatt Regency in San Diego. A live webcast of AC... 
Printer Friendly Version
10/06/09ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2009
SAN DIEGO--(BUSINESS WIRE)--Oct. 6, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the JMP Securities Healthcare Focus Conference on Tuesday, October 6, 2009 at 3:00 p.m. Eastern Time at The New York Palace Hotel in New York City. ... 
Printer Friendly Version
10/06/09ACADIA Pharmaceuticals Provides Update on Pimavanserin Collaborative Development Program
SAN DIEGO--(BUSINESS WIRE)--Oct. 6, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with Biovail Laboratories International SRL (&... 
Printer Friendly Version
09/01/09ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
Pimavanserin Misses Primary Endpoint of Antipsychotic Efficacy; Meets Key Secondary Endpoint of Motoric Tolerability Conference Call Scheduled for Today, September 1, at 8:00 A.M. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Sep. 1, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the first pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis, or P... 
Printer Friendly Version
08/05/09ACADIA Pharmaceuticals Reports Second Quarter 2009 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the second quarter and six months ended June 30, 2009. ACADIA reported a net loss of $12.7 million, or $0.34 per common share, for the ... 
Printer Friendly Version
07/29/09ACADIA Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 5, 2009
ACADIA to Host Conference Call and Webcast on Wednesday, August 5, 2009, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Jul. 29, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 20... 
Printer Friendly Version
06/03/09ACADIA Pharmaceuticals to Present at the Eighth Annual Needham Life Sciences Conference on June 10, 2009
SAN DIEGO--(BUSINESS WIRE)--Jun. 3, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Eighth Annual Needham Life Sciences Conference on Wednesday, June 10, 2009 at 9:30 a.m. Eastern Time at The New York Palace Hotel in New York City. ... 
Printer Friendly Version
05/13/09ACADIA Pharmaceuticals to Present at the Eighth Annual JMP Securities Research Conference on May 19, 2009
SAN DIEGO--(BUSINESS WIRE)--May. 13, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Eighth Annual JMP Securities Research Conference on Tuesday, May 19, 2009 at 2:30 p.m. Pacific Time at The Ritz-Carlton Hotel in San Francisco. ... 
Printer Friendly Version
05/11/09ACADIA Pharmaceuticals Reports First Quarter 2009 Financial Results
SAN DIEGO--(BUSINESS WIRE)--May. 11, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the first quarter ended March 31, 2009. ACADIA reported a net loss of $15.0 million, or $0.40 per common share, for the first quarter ... 
Printer Friendly Version
05/06/09ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
Top-Line Data Expected in the Third Quarter of 2009 SAN DIEGO & TORONTO--(BUSINESS WIRE)--May. 6, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) and Biovail Corporation (NYSE:BVF) (TSX:BVF), today announced the completion of enrollment in the first pivotal Phase III clinical trial of pimavanserin in patients with Parkinson’s disease psychosis (PDP). Top-line results from this trial are expected to be announced by the end of the third quarter of 20... 
Printer Friendly Version
05/05/09ACADIA Pharmaceuticals to Announce First Quarter 2009 Financial Results on May 11, 2009
ACADIA to Host Conference Call and Webcast on Monday, May 11, 2009, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--May. 5, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2009 on... 
Printer Friendly Version
05/04/09ACADIA Pharmaceuticals and Biovail Form Collaboration to Develop and Commercialize Pimavanserin in North America
Conference Call Scheduled for Today, May 4, 2009, at 8:30 a.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--May. 4, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) today announced that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to co-develop and commercialize pimavanserin, ACADIA’s proprietary and selective 5-HT2A inverse agonist, in the United States and Canada. ACADIA retains rights t... 
Printer Friendly Version
03/25/09ACADIA Pharmaceuticals and Meiji Seika Kaisha Form Collaboration to Develop and Commercialize a New Class of Pro-Cognitive Schizophrenia Drugs
Meiji Seika Granted Rights to Develop and Commercialize Products in Asian Territory; ACADIA Retains All Rights in the Rest of the World SAN DIEGO--(BUSINESS WIRE)--Mar. 25, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) and Meiji Seika Kaisha, Ltd. (TSE:2202) today announced that they have established a collaboration to develop and commercialize a novel class of pro-cognitive drugs to treat patients with schizophrenia and related disorders in Japan and several ... 
Printer Friendly Version
03/09/09ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2008
SAN DIEGO--(BUSINESS WIRE)--Mar. 9, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the fourth quarter and year ended December 31, 2008. ACADIA reported a net loss of $14.0 million, or $0.38 per common share, for the fo... 
Printer Friendly Version
03/04/09ACADIA Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference on March 11, 2009
SAN DIEGO--(BUSINESS WIRE)--Mar. 4, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Barclays Capital Global Healthcare Conference on Wednesday, March 11, 2009, at 9:30 a.m. Eastern Time at the Loews Miami Beach Hotel in Miami Beach, Florida.... 
Printer Friendly Version
03/02/09ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
ACADIA to Host Conference Call and Webcast on Monday, March 9, 2009, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Mar. 2, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the fourth quarter and year ended Decemb... 
Printer Friendly Version
02/03/09ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 10, 2009
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the BIO CEO & Investor Conference 2009 on Tuesday, February 10, 2009, at 10:00 a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. A live webcast o... 
Printer Friendly Version
01/07/09ACADIA Pharmaceuticals Awarded Grant from The Michael J. Fox Foundation for the Development of Novel ER-beta Agonists for the Treatment of Parkinson’s Disease
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has been awarded a grant from The Michael J. Fox Foundation for the development of novel estrogen receptor beta (ER-beta) agonists for the treatment of Parkinson’s disease. The grant of up to ... 
Printer Friendly Version
11/25/08ACADIA Pharmaceuticals to Present at The 20th Annual Piper Jaffray Health Care Conference on December 3, 2008
SAN DIEGO, Nov 25, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at The 20th Annual Piper Jaffray Health Care Conference on Wednesday, December 3, 2008, at 10:30 a.m. Eastern Time at The New York Palace Hotel in New York City. A live ... 
Printer Friendly Version
11/05/08ACADIA Pharmaceuticals Reports Third Quarter 2008 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter ended September 30, 2008. ACADIA reported a net loss of $15.6 million, or $0.42 per common share, for the third quarter of 2008 compared to a net loss of $16.0 mil... 
Printer Friendly Version
11/03/08ACADIA Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008
SAN DIEGO--(BUSINESS WIRE)--Nov. 3, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at The Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11, 2008, at 11:35 a.m. Eastern Time at The New York Palace Hotel in New York City. A live webcast of ACADIA's presen... 
Printer Friendly Version
10/29/08ACADIA Pharmaceuticals to Announce Third Quarter 2008 Financial Results on November 5, 2008
ACADIA to Host Conference Call and Webcast on Wednesday, November 5, 2008, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2008... 
Printer Friendly Version
10/21/08ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences: -- The BIOCOM Investor Conference 2008 on Tuesday, October 28, 2008, at 3:30 p.m. Pacific Time at the Hyatt Regency in San Diego. -- BIO I... 
Printer Friendly Version
09/29/08ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2008
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the JMP Securities Healthcare Focus Conference on Monday, October 6, 2008, at 1:00 p.m. Eastern Time at Le Parker Meridien Hotel in New York City. A live webcast of ACADIA's presentation will be accessible o... 
Printer Friendly Version
09/05/08ACADIA Pharmaceuticals Files Registration Statement as Required by Previously Announced Committed Equity Financing Facility
SAN DIEGO--(BUSINESS WIRE)--Sept. 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it filed a registration statement as required under the terms of its previously announced Committed Equity Financing Facility (CEFF) with Kingsbridge Capital Limited. Under the terms of the CEFF, ACADIA has acces... 
Printer Friendly Version
08/28/08ACADIA Pharmaceuticals to Present at The Thomas Weisel Partners Healthcare Conference on September 4, 2008
SAN DIEGO, Aug 28, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at The Thomas Weisel Partners 2008 Healthcare Conference on Thursday, September 4, 2008, at 2:40 p.m. Eastern Time at the Four Seasons Boston Hotel. A live webcast of AC... 
Printer Friendly Version
08/05/08ACADIA Pharmaceuticals Secures Committed Equity Financing Facility
SAN DIEGO, Aug 05, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has entered into a Committed Equity Financing Facility (CEFF) with Kingsbridge Capital Limited in which Kingsbridge has committed to provide up to $60 million of capital during the next three years through the purchase... 
Printer Friendly Version
08/05/08ACADIA Pharmaceuticals Announces Second Quarter 2008 Financial Results and Strategic Restructuring
SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the second quarter ended June 30, 2008 and announced a strategic restructuring. ACADIA will focus on developing a portfolio of its four most advanced product candidates, consisting o... 
Printer Friendly Version
07/29/08ACADIA Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
ACADIA to Host Conference Call and Webcast on Tuesday, August 5, 2008, at 8:30 a.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--July 29, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2008 on... 
Printer Friendly Version
06/16/08ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial
-- Conference Call Scheduled for Today, June 16, 2008, at 8:30 a.m. Eastern Time -- SAN DIEGO--(BUSINESS WIRE)--June 16, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) today announced results from its Phase IIb trial with ACP-104 for the treatment of schizophrenia. The study did not meet its primary endpoint of antipsychotic efficacy or any of the secondary endpoints. Neither dose of ACP-104 demonstrated improved efficacy as compared to placebo. The most c... 
Printer Friendly Version
06/04/08ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--June 4, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences: The Seventh Annual Needham & Company Biotechnology and Medical Technology Conference on Wednesday, June 11, 2008, at 1:30 p.m. Eastern Time at ... 
Printer Friendly Version
05/14/08ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--May 14, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences: The 2008 Citi Investment Research Global Health Care Conference on Thursday, May 22, 2008, at 10:30 a.m. Eastern Time at the Hilton New York i... 
Printer Friendly Version
05/05/08ACADIA Pharmaceuticals Announces Election of Laura A. Brege to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--May 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the election of Laura A. Brege to its board of directors. Ms. Brege will fill a vacancy on the Board and serve as a Class III director. The terms of the Class III directors expire at the annual meeting of stockholders in 2... 
Printer Friendly Version
05/05/08ACADIA Pharmaceuticals Reports First Quarter 2008 Financial Results
SAN DIEGO--(BUSINESS WIRE)--May 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system (CNS) disorders, today reported its unaudited financial results for the first quarter ended March 31, 2008. ACADIA reported a net loss of $16.4 million, or $0.44 per common share, for the first quarter of 2008 compared to a net loss of $12.6 mil... 
Printer Friendly Version
04/30/08ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--April 30, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences: Deutsche Bank's 33rd Annual Health Care Conference on Wednesday, May 7, 2008, at 9:30 a.m. Eastern Time at the InterContinental Boston Hote... 
Printer Friendly Version
04/28/08ACADIA Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 5, 2008
ACADIA to Host Conference Call and Webcast on Monday, May 5, 2008, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--April 28, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2008 on M... 
Printer Friendly Version
04/16/08ACADIA Pharmaceuticals to Present Data from Its Phase II Trial with Pimavanserin for Parkinson's Disease Psychosis at the 60th American Academy of Neurology Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--April 16, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the company will present data from its previously reported Phase II trial with pimavanserin for Parkinson's disease psychosis (PDP) at the 60th American Academy of Neurology Annual Meeting on April 16, 2008 in Chica... 
Printer Friendly Version
04/04/08ACADIA Pharmaceuticals to Present Preclinical Data on ACP-104, ACP-105 and Its Muscarinic Discovery Program at Experimental Biology 2008 Meeting
SAN DIEGO--(BUSINESS WIRE)--April 4, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the company will present preclinical data on its ACP-104 schizophrenia program, its ACP-105 Selective Androgen Receptor Modulator (SARM) program, and its muscarinic discovery program at the Experimental Biology 2008... 
Printer Friendly Version
03/31/08ACADIA Pharmaceuticals Initiates Second Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
SAN DIEGO--(BUSINESS WIRE)--March 31, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated its second Phase III trial designed to evaluate the safety and efficacy of pimavanserin as a treatment for Parkinson's disease psychosis (PDP). "The start of our second Phase III pivotal trial r... 
Printer Friendly Version
03/28/08ACADIA Pharmaceuticals to Present at the 8th Annual Fortis Bank Biotechnology Conference
SAN DIEGO, Mar 28, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at The 8th Annual Fortis Bank Biotechnology Conference on Thursday, April 3, 2008, at 10:00 a.m. Western European Time at the Four Seasons Hotel London in London, England. About ACADIA Pharmaceuticals ACADI... 
Printer Friendly Version
03/11/08ACADIA Pharmaceuticals to Present at Lehman Brothers 11th Annual Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--March 11, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at Lehman Brothers 11th Annual Global Healthcare Conference on Tuesday, March 18, 2008, at 2:00 p.m. Eastern Time at the Loews Miami Beach Hotel in Miami Beach, Florida. A live webcast of ACADIA... 
Printer Friendly Version
03/05/08ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007
SAN DIEGO--(BUSINESS WIRE)--March 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the fourth quarter and year ended December 31, 2007. ACADIA reported a net loss of $17.0 million, or $0.46 per common share, for the fourth quarter of 2007 compared to a n... 
Printer Friendly Version
02/27/08ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 5, 2008
ACADIA to Host Conference Call and Webcast on Wednesday, March 5, 2008, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Feb. 27, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the fourth quarter and year ended December ... 
Printer Friendly Version
02/12/08ACADIA Pharmaceuticals Appoints John J. Kaiser as Vice President, Strategic Marketing and Commercial Development
SAN DIEGO, Feb 12, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the appointment of John J. Kaiser as Vice President, Strategic Marketing and Commercial Development. Mr. Kaiser joins ACADIA from Eli Lilly & Co. where he held a variety of marketing and commercial management positions over a... 
Printer Friendly Version
02/05/08ACADIA Pharmaceuticals Announces Presentation of Data on Pimavanserin Co-Therapy at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
New Data Demonstrate Less Increase in Serum Glucose Levels With Pimavanserin Co-Therapy SAN DIEGO, Feb 05, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Murray Rosenthal, D.O., a Fellow of the American Psychiatric Association, will present data from ACADIA's pimavanserin Phase II schiz... 
Printer Friendly Version
02/04/08ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2008
SAN DIEGO, Feb 04, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the BIO CEO & Investor Conference 2008 on Tuesday, February 12, 2008, at 10:15 a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. A live webcast of ACADIA's presentation will be accessible... 
Printer Friendly Version
back to top